A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium plus olodaterol fixed dose combination (2.5 microg/5 or 10 microg; 5 microg/5 or 10 microg) (delivered by the Respimat(R) Inhaler) compared with the individual components (2.5 and 5 microg tiotropium, 5 or 10 microg olodaterol) (delivered by the Respimat(R) Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium plus olodaterol fixed dose combination (2.5 microg/5 or 10 microg; 5 microg/5 or 10 microg) (delivered by the Respimat(R) Inhaler) compared with the individual components (2.5 and 5 microg tiotropium, 5 or 10 microg olodaterol) (delivered by the Respimat(R) Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary) ; Olodaterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 30 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 23 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top